Transient receptor potential mucolipin 1 (TRPML1) is a Ca 2+-releasing cation channel that mediates the calcium signalling and homeostasis of lysosomes. Mutations in TRPML1 lead to mucolipidosis ...

A new U-M study identified two critical components of this cell clearing process: an essential calcium channel protein, TRPML1, that helps the so-called garbage collecting cells, called ...

In a recent paper published in Nature, researchers from the University of Michigan have discovered that simultaneously targeting PIKfyve and KRAS-MAPK can eliminate tumors in preclinical human and ...

Additionally, the company is expanding the development of their potent, selective, orally bioavailable small molecule PIKfyve inhibitors to include the treatment of COVID-19. Verge discovered the ...

Its candidates are small-molecule agonists of TRPML1, a calcium channel found in lysosomes, the enzyme-filled sacs that break down cellular debris. TRPML1 is important for lysosomal health ...

Merck has struck a deal to buy Calporta Therapeutics for up to $576 million. The takeover centers on TRPML1 agonists designed to treat neurodegenerative disorders by clearing toxic proteins from ...

Tenvie’s diverse pipeline also includes programs focused on neuroprotective pathways, including TRPML1 and TMEM175. “Tenvie was purpose-built to apply deep biological and chemical insights to ...

Caraway’s Chief Executive Officer, Martin D. Williams, will present recent advances in the Company’s TRPML1 program at the Fall Life Sciences Private Company Showcase, co-hosted by BMO Capital ...

AcuraStem announced that it has officially inked a license agreement with Takeda to develop and commercialize its PIKfyve targeted therapeutics, including AS-202, an innovative antisense ...